Evidence map›Paper›PMID 36172116›Full record

ArticleAnnals of translational medicine2022

Association between

Yiruo Zhang, Xin Huang, Ruiqi Niu, Chenghui Li, Jingdan Pang, Pingping Liu, Hiroyuki Adachi, Akikazu Kawase, Fumihiro Yamaguchi, Yingying Du

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of translational medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 6 institutions in 2 countries.

Yiruo Zhang *Department of Oncology, The First Affiliated Hospital of Anhui Medical University, Hefei, China.
Xin Huang *Department of Oncology, The First Affiliated Hospital of Anhui Medical University, Hefei, China.
Ruiqi NiuDepartment of Oncology, The First Affiliated Hospital of Anhui Medical University, Hefei, China.
Chenghui LiDepartment of Oncology, Anqing Municipal Hospital, Anqing, China.
Jingdan PangDepartment of Oncology, The First Affiliated Hospital of Anhui Medical University, Hefei, China.
Pingping LiuDepartment of Oncology, The First Affiliated Hospital of Anhui Medical University, Hefei, China.
Hiroyuki AdachiDepartment of Thoracic Surgery, Kanagawa Cancer Center, Yokohama, Japan.
Akikazu KawaseFirst Department of Surgery, Hamamatsu University School of Medicine, Shizuoka, Japan.
Fumihiro YamaguchiDepartment of Respiratory Medicine, Showa University Fujigaoka Hospital, Yokohama, Japan.
Yingying DuDepartment of Oncology, The First Affiliated Hospital of Anhui Medical University, Hefei, China.
Anhui Medical University · CNFirst Affiliated Hospital of Anhui Medical University · CNAnqing City Hospital · CNHamamatsu University School of Medicine · JPKanagawa Prefectural Hospital Organization · JPShowa University Fujigaoka Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) is an important treatment for lung adenocarcinoma patients with Methods: Tumor tissues were collected from stage IV lung adenocarcinoma patients with Results: T790M mutation rates were 37.93% (11/29) and 42.50% (17/40) in the Conclusions: After resistance to the first-generation EGFR-TKI treatment, the occurrence of T790M mutation may be related to the expression of EGFR mutant protein in patients with

Indexed as

EGFR-tyrosine kinase inhibitor (EGFR-TKI)epidermal growth factor receptor (EGFR)Lung adenocarcinomaT790M mutation

Identifiers

PMID36172116
PMCPMC9511196
OpenAlexW4296088938

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.